Stimulating Conversations: NeuroOne's First Podcast Explores Potential Thin Film Electrode
NeuroOne's podcast, “Behind the Electrodes,” welcomes guests from the field of neuroscience to provide insight on the developing technologies and practices relevant to doctors and patients alike.
The inaugural episode of our podcast, Behind the Electrodes, features an interview with Dave Rosa, CEO, NeuroOne Medical Technologies Corporation. Rosa provides updates on the potential of thin-film electrodes for less invasive brain applications and why NeuroOne’s Evo™ Cortical Electrodes (Evo), the first FDA-cleared thin-film electrodes for recording, monitoring and stimulating brain tissue for up to 30 days, are a game changer in the neurotechnology space – and could potentially revolutionize brain surgery.
Rosa, whose lifelong passion for helping people led him to become CEO at NeuroOne, envisioned how the company could introduce and commercialize its technology to impact conditions, such as epilepsy, Parkinson’s disease, dystonia, essential tremors and pain management for failed back surgery syndrome.
Advancing Neuroscience and Neurosurgery
Early on, Rosa recognized that brain imaging required significant improvement and cortical electrodes needed to be less invasive to enhance the patient experience. The result: NeuroOne’s technological advances are now drawing keen interest from neurologists and neurosurgeons.
“Historically, brain surgeries are very invasive, requiring removal of the top of the skull,” Rosa said during the episode. “This makes surgery daunting for patients. Given that half of brain surgeries are for pediatric patients, reducing invasiveness would make the decision to allow brain surgery on infants and adolescents much less frightening for parents.”
Progress in electrodes in the past 30 years had been minimal and primarily applicable only for research. Many electrodes had issues with fluid penetrating between the film or were not robust enough to handle repeated recordings. Because most companies in this space were more focused on hardware and software, Rosa saw an opportunity to improve electrode technology by making them thinner and more flexible.
Today, Evo are the first electrode from the thin film platform to receive Food and Drug Administration 510(k) clearance. Evo are thin film flexible strip and grid electrodes intended for temporary (less than 30 days) recording, monitoring and stimulation of brain tissue. Evo are on track to soon hit the market, offering a less invasive, more cost-effective solution to enhance neurosurgery for people with brain conditions.
The Future of Neurotechnology
A study performed at the Mayo Clinic determined that Evo caused less inflammation, improved resolution and, with fully automated manufacturing, improved upon the limitations and inconsistencies of available electrodes that were made by hand.
“Evo may have the potential to change the landscape of neurosurgical procedures, and we are very excited by the ability to dramatically increase the number of contacts on our electrodes without increasing their footprint,” Rosa said. “Adding several thousand contact points has the potential to combine with AI systems in a way that would enable Evo to be used for more complex conditions. This is where NeuroOne is heading.”